Detection of human T-cell lymphotropic virus Type-1

among patients with malignant hematological diseases

in Capital of Iran, Tehran by Monavari, Seyed Hamidreza et al.
Journal of General and Molecular Virology Vol. 3(5), pp. 67-70, November 2011     
Available online at http://www.academicjournals.org/JGMV 
ISSN 2141-6648 ©2011 Academic Journals 
DOI: 10.5897/JGMV11.021  
 
 
 
Full Length Research paper 
 
Detection of human T-cell lymphotropic virus Type-1 
among patients with malignant hematological diseases 
in Capital of Iran, Tehran 
 
Seyed Hamidreza Monavari1*, Hossein Keyvani1, Hamidreza mollaie2, Mehdi fazlalipour2, 
Farzin sadeghi2, Mostafa Salehi-Vaziri1, Roghaeh mollaie3 and Farah Bokharaei-Salim1 
 
1Department of Virology and Antimicrobial Resistance Research Center, Tehran University of Medical Sciences,  
Tehran, Iran. 
2Department of Medical Virology, Tehran University of Medical Sciences, Tehran, Iran. 
3Department of Medical Technology, Hazrat rasool Hospital, Tehran University of Medical Sciences, Tehran, Iran. 
 
Accepted 13 October, 2011 
 
Human T-cell lymphotropic virus type-1 (HTLV-1) is a deltaretrovirus linked causally to adult T-cell 
leukemia or lymphoma (ATL), and HTLV-1-associated myelopathy/tropical spastic paraparesis 
(HAM/TSP). The aim of this study was to detect HTLV-1 infection in patients with malignant 
hematological diseases and also determining the prevalence of HTLV-1 in these patient groups. Sixty 
patients with malignant hematological diseases were included in the study and tested by enzyme-linked 
immunosorbent assay (ELISA) for anti-HTLV-1, and Real time-PCR for the sequences from HTLV-1 tax 
gene. The mean age of patients was 33.9 ± 18.3 years. 18 of the subjects were found HTLV-1 
seropositive using ELISA and the viral prevalence by Real time-PCR was 12%. HTLV-1 was found in 
25% of patients with acute myelogenous leukemia (AML), 58.3% of patients with chronic myelogenous 
leukemia (CML), 16.7% of patients with acute lymphoblastic leukemia (ALL), and no detected in patients 
with lymphoma. The present study revealed that HTLV-1 is prevalent in patients with malignant 
hematological diseases and in our study. The major HTLV-1 associated syndromes were chronic 
myelogenous leukemia and acute lymphoblastic leukemia.  
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INTRODUCTION 
 
A type C retrovirus human T-cell lymphotropic virus type 
1 (HTLV-1) is the causative agent of two distinct human 
diseases, adult T-cell leukemia or lymphoma (ATL), and 
a chronic progressive demyelinating disorder known as 
HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP) (Matsuoka and Jeang, 2007). 
HTLV-1 infection has also been associated with a variety 
of chronic inflammatory diseases such as uveitis 
(Mochizuki et al., 1996), Sjo¨gren’s syndrome (Eguchi et 
al., 1995), chronic arthropathy (Hasunuma, 1997), 
infective dermatitis (Lee and Schwartz, 2011), 
polymyositis     synovitis     (Sowa,     1992),      thyroiditis  
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(Desailloud and Hober, 2009), and bronchioalveolar 
pneumonitis (Sugimoto et al., 1993). The role of HTLV-1 
infection in these disorders is still under investigation. It is 
estimated that 10 to 20 million people world-wide are 
infected with HTLV-1 (Johnson et al., 2001). This 
infection is endemic in southern Japan, the caribbean 
basin, central Africa, central and south America, the 
melanesian islands in the Pacific basin, and in the 
aboriginal population in Australia (Proietti et al., 2005). In 
Iran, this virus has been found in isolated pockets that 
HTLV-1 infection is endemic (Khorasan, the northeastern 
province of Iran). The prevalence of HTLV-1 infection in 
Mashhad was 0.77% among blood bank donors (Tarhini 
et al., 2009). However, little is known on the prevalence 
of HTLV-1 in patients with malignant hematological 
diseases in Iran, including a possible HTLV-1 association 
with other malignancies (Table 1). 
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Table 1. Prevalence of HTLV-1 among patients with malignant hematological diseases in Iran. 
 
Hematological malignancies Patient No Mean age Male / female HTLV-I antibody positive (%) HTLV-I PCR positive (%) 
Acute myelogenous leukemia (AML) 26 29.8±12.2 19/7 8 (30.8) 3 (11.5) 
Chronic myelogenous leukemia (CML) 21 51±14.6 16/5 7 (33.3) 7 (33.3) 
Lymphoma 3 27.3±2.5 2/1 1 (33.3) 0 (0) 
Acute lymphoblastic leukemia (ALL) 10 12.3±6.2 7/3 2 (20) 2 (20) 
Total 60 33.9±18.3 44/16 18 (30) 12 (20) 
 
 
 
The association between retroviruses and 
hematologic malignancies is also described. 
There have been few studies on the association 
between human T cell lymphotropic virus type 1 
(HTLV-1) infection and malignancy risk (Inoue et 
al., 2008). It  is  still  controversial  whether  or  not 
HTLV-1 infection affects the incidence of several 
malignancies. Adedayo et al. (2004) found an 
association between HTLV-1 and lymphoid 
malignancies in Dominican population. There are 
case reports of HTLV-1 in lymphoid malignancies 
except ATL (Starkebaum et al., 1987). Little is 
known on the prevalence of HTLV1 in patients 
with various hematologic. The association 
between retroviruses and hematologic malignan-
cies is also described. There have been few 
studies on the association between human T cell 
lymphotropic virus type 1 (HTLV-1) infectionand 
malignancy risk (Inoue et al., 2008). It is still 
controversial whether or not HTLV-1 infection 
affects the incidence of several malignancies.  
Adedayo et al. (2004) found an association 
between HTLV-1 and lymphoid malignancies in 
Dominican population. There are case reports of 
HTLV-1 in lymphoid malignancies except ATL 
(Starkebaum et al., 1987). Little is known on the 
prevalence of HTLV1 in patients with various 
hematologic malignancies, therefore we studied 
the prevalence of HTLV1 carriers among patients 
myelogenous leukemia (CML), acute lymphoblastic 
leukemia    with    acute    myelogenous   leukemia  
(AML), chronic (ALL) and lymphoma. 
 
 
MATERIALS AND METHODS 
 
Study design 
 
In this cross-sectional study 60 patients with established 
malignant hematological diseases who were admitted to 
oncology Unit of Hazrate Rasul Hospital, Tehran, Iran, from 
2009 to 2010 were enrolled. Diagnosis of malignancy was 
confirmed based on pathology (histology) findings. 
The malignancies were as follows: acute myelogenous 
leukemia (AML) (26 cases), chronic myelogenous leukemia 
(CML) (21 cases), acute lymphoblastic leukemia (ALL) (10 
cases) and lymphoma (3 cases). 
 
 
Collection and preparation of samples 
 
About 5 ml of peripheral blood were collected from each 
patient into EDTA-containing vacutainer tubes. Plasma 
was stored at -70°C until anti HTLV-1 antibody analysis. 
Blood buffy coat were isolated from EDTA-treated blood by 
centrifugation and stored at -70°C for later detection. All 
patients gave written consent to participate in this study, 
which conforms to the guidelines of the 1975 Declaration of 
Helsinki. 
 
 
Immunoassay for anti-HTLV-1 
 
Serum samples were examined for anti HTLV-I antibody by 
enzyme-linked immunosorbent assay (ELISA) method 
using  anti HTLV-1 antibody kit (ELISA; Dia. Pro Diagnostic 
Bioprobes, Milan, Italy). Assay procedures and the 
interpretation of the results were performed in accordance 
with the instructions provided by the manufacturer. 
 
 
Real time polymerase chain reaction 
 
To detect HTLV-1 provirus in peripheral blood cells DNA 
was extracted from 200 µl blood Buffy coat using the High 
pure extraction kit (Roche Diagnostics GmbH, Mannheim, 
Germany). Quantitative determination of the amplified 
products was done with the Rotor Gene 6000 (Corbett 
Research, Australia) Real-time detection system in 
accordance with the instructions provided by the 
manufacturer and subjected to PCR with a Maxima probe 
qPCR Master Mix (2X) kit (Fermentas, Germany). The 
primer set for the HTLV- 1 tax gene was PXF (5´-
CAAACCGTCAAGCACAGCTT-3´) positioned at 7163 to 
7182 and PXR (5´-TCTCCAAACACGTAGACTGGGT- 3´) 
positioned at 7385 to 7364 and the probe for HTLV-1 tax 
gene was PXT (5´-
TTCCCAGGGTTTGGACAGAGTCTTCT- 3´)  positioned at 
7331  to 7355 (Gabet et al., 2003). The thermal cycler 
profile is optimized and validated with heat activation (15 
min at 95°C) of hot-start Taq polymerase was followed by 
40 cycles of denaturation (30 s at 95°C), annealing (30 s at 
50°C), and extension (30 s at 72°C). For positive control, 
DNA was extracted from a HTLV-1 producing human T-cell 
line (MT-2). 
 
 
Statistical analysis 
 
Data analyses were done by SPSS software version 11 
(SPSS, Chicago, IL). Descriptive results were presented as 
frequencies, and 95% confidence intervals.                                                                         
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Table 2. Demographic characteristics of patients positive to HTLV-1. 
 
Case ELISA PCR Syndrome Duration of blood transfusion in month Age/gender 
1 + - Lymphoma Unknown 25/M 
2 + + CML 2 69/M 
3 + + AML 2 50/F 
4 + - AML 3 31/M 
5 + + AML 1 31/M 
6 + + CML 2 42/F 
7 + + CML 3 42/M 
8 + + CML 3 36/M 
9 + + AML 5 21/M 
10 + + CML 2 54/M 
11 + + CML 5 43/F 
12 + + CML 6 65/M 
13 + - AML 4 31/M` 
14 + + ALL 5 21/M 
15 + + ALL 1 4/F 
16 + - AML 2 41/M 
17 + - AML 4 25/M 
18 + - AML 3 32/M 
 
 
 
The correlation between different factors was evaluated by 
chi-square test (x2), or Fisher’s exact test when an 
expected value was less than 5. 
 
 
RESULTS 
 
Sixty patients with established malignant 
hematological diseases were recruited in this 
study. The mean age of patients was 33.9 ± 18.3 
years. Out of 60 patients, 44 (73.3%) were male. 
According to the type of hematological 
malignancy, 26 (43.3%) with acute myelogenous 
leukemia (AML), 21 (35%) with chronic 
myelogenous leukemia (CML), 3 (5%) with 
lymphoma, and 10 (16.6%) with acute 
lymphoblastic  leukemia  (ALL)  consist  our  study  
population (Table 2). 
Eighteen of sixty cases of malignant 
hematological diseases were positive with ELISA 
for HTLV-1 antibody, obtaining an HTLV-1 
seroprevalence of 30% (18/60). The Molecular 
method of Real time-PCR that amplifies 
sequences from the tax region provided a viral 
prevalence of 20% (12/60). Statistical 
comparisons showed that ELISA detected higher 
positive results (P < 0.05) than Real time-PCR. 
HTLV-1 antibody was found in 30.8% of patients 
with acute myelogenous leukemia, 33.3% of 
patients with chronic myelogenous leukemia, 20% 
of patients with acute lymphoblastic leukemia and 
33.3% in lymphoma patients. In our study the 
major HTLV-1 associated syndromes were 
chronic    myelogenous     leukemia     and    acute  
lymphoblastic leukemia.  
In this study, a significant difference was seen; 
the history of blood transfusion (p=0.04) between 
patients with positive and negative results for 
HTLV-1 infection. 
 
 
 
DISCUSSION 
 
HTLV-1 causes adult T-cell leukemia (ATL) and 
HTLV l-associated myelopathy (tropical spastic 
paraparesis), a nononcogenic neurologic disease, 
arthropathy, and Sjogren’s syndrome, infective 
dermatitis of childhood, hyperinfective 
strongyloidiasis (Gotuzzo et al., 1999), and 
Norwegian scabies (Blas et al., 2005). HTLV-1 is 
cell  associated  and  is  spread in cells after blood  
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transfusion, sexual intercourse, or breastfeeding. The 
information and understanding of HTLV-1 prevalence in 
different population and patients groups is crucial 
because it may be useful in establishing prophylactic 
measures to decrease rates of viral transmission from 
infected individuals.  
In the present study, we demonstrate that the 
prevalence of HTLV-1 infection in patients with malignant 
hematological diseases in Iran is 20% and HTLV-1 
seroprevalence is 30%. Whereas the gold standard 
method for the diagnosis of HTLV-1 infection is the 
detection of HTLV-1 genome in the specimen of patients, 
it seems that the prevalence of HTLV-1 infection in our 
study population is about 20%.  
There are several reports which demonstrated a 
comparable HTLV-1 prevalence to our study. Farias de 
Carvalho et al. (1997) found a seroprevalence of 28.9% 
among patients with T-cell lymphoid malignancies in 
Brazil. Adedayo and Shehu (2004) found a 38.6% of 
HTLV-1 seropositives in all hematological malignancies in 
India. Miyagi et al. (2002) found a HTLV-1 prevalence of 
26.1% in 88 cases of non-Hodgkin’s lymphoma in Japan. 
Barrientos et al. (2005) in southern Chile found an HTLV-
1/2 viral prevalence in patients with malignant hematolo-
gical diseases 18%, and in chronic lymphoproliferative 
disorders 27% (Barrientos, 2005). The overall HTLV-1 
prevalence rate found in our study group is greater than 
that seen in some studies but is closed to the others.  
On the other hand, HTLV-1 is among the infectious 
agents that can be transmitted via blood transfusion 
(Matsuoka and Jeang, 2007). In the present study, 
significant difference was seen between patients with and 
without HTLV-1 infection. These patients with HTLV-1 
infection may acquire this infection from blood 
transfusion, despite all of the requirements for screening 
the blood supply. Therefore, the present study suggests 
that serious consideration must be given to prevent 
HTLV-I infection via transfusion in hematological 
malignanant patients. Routine serological screening for 
HTLV-I antibody and detection of HTLV-1 genome in 
blood donors is indicated to permit deferral of blood 
product donations by asymptomatic HTLV-1 carriers. 
In conclusion, the results of this study show an 
association between HTLV-1 and malignant 
hematological diseases. Therefore, the possibility of 
HTLV-1 infection should be considered in patients who 
suffer malignant hematological diseases. 
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